Three-Dimensional Quantitative Structure-Property Relationships

The Practice of Medicinal Chemistry: Second Edition

Volumn , Issue , 2003, Pages 405-416

  Cruciani, Gabriele ^a   Carosati, Emanuele ^a   Clementi, Sergio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN BONDS; MOLECULES; REGRESSION ANALYSIS;

BIOLOGICAL RESPONSE; COMPARATIVE MOLECULAR FIELD ANALYSIS; ELECTROSTATIC POTENTIALS; MOLECULAR MODELING TECHNIQUES; PHYSICAL CHARACTERISTICS; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIPS (QSAR); STRUCTURAL DESCRIPTORS; THREE-DIMENSIONAL QUANTITATIVE STRUCTURES;

COMPUTATIONAL CHEMISTRY;

EID: 84942851953     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012744481-9/50029-5     Document Type: Chapter

References (57)

1. Exploring QSAR: Hydrophobic, Electronic, and Steric Constants 1995, 348. American Chemical Society, New York. C. Hansch, A. Leo, D. Khoekman (Eds.).
2. Fujita T. The role of QSAR in drug design. Drug Design: Fact or Fantasy? 1984, 19-33. Academic Press, Washington, DC. G. Jolles, K.R.H. Wolldridge (Eds.).
3. Boyd D.B. Successes of computer-assisted molecular design. Reviews in Computational Chemistry 1990, 355-371. VCH, London. K.B. Lipkowitz, D.B. Boyd (Eds.).
4. Classical and three-dimensional QSAR in agrochemistry 1995, 342. American Chemical Society, New York. C. Hansch, T. Fujita (Eds.).
5. Cramer R.D., Patterson D.E., Bunce J.D. Comparative molecular field analysis (CoMFA): I. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110:5959-5967.
6. Pastor M., Cruciani G., Clementi S. Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. J. Med. Chem. 1997, 40:1455-1464.
7. Martin Y.C. 3D QSAR: current state, scope and limitations. 3D QSAR in Drug Design 1998, 3-23. Kluwer, Washington, DC. H. Kubinyi (Ed.).
8. Cruciani G., Clementi S., Baroni M., Pastor M. Recent developments in 3D QSAR methodologies. Alfred Benzon Symposium 1998, 42:87-97. Munksgaard, Dordrecht. T. Liljefors, F.S. Jorgensen, P. Krogsgaard-Larsen (Eds.).
9. Clementi S., Cruciani G., Riganelli D., Valigi R. GOLPE: merits and drawbacks in 3D-QSAR. QSAR and Molecular Modeling: Concepts, Computational Tools and Biological Applications 1995, 408-414. Prous Sci., Copenhagen. F. Sanz (Ed.).
10. Goodford P.J. A computational procedure for determining energetically favourable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28:849-857.
11. Boobbyer D.N.A., Goodford P.J., Mcwhinnie P.M., Wade R.C. New hydrogen-bond potentials for use in determining energetically favourable binding sites on molecules of known structure. J. Med. Chem. 1989, 32:1083-1094.
12. Wade R., Clerk K.J., Goodford P.J. Further development of hydrogen bond function for use in determining energetically favourable binding sites on molecules of known structure. Ligand probe groups with the ability to form two hydrogen bonds. J. Med. Chem. 1993, 36:140-147.
13. Floershein P., Nozulak J., Weber H.P. Experience with comparative molecular field analysis. Trends in QSAR and Molecular Modeling '92 1993, 227-232. ESCOM, Barcelona. C.G. Wermuth (Ed.).
14. Carrupt P.A., Gaillard P., Billois F., Weber P., Testa B., Meyer C., Perez S. The Molecular lipophilicity potential (MLP): a new tool for logP calculation and docking, and in comparative molecular field analysis (CoMFA). Lipophilicity in Drug Action and Toxicology 1995, 195-215. VCH, Leiden. V. Pliska, B. Testa, H. van de Waterbeemd (Eds.).
15. Kellogg G.E., Abraham D.J. KEY, LOCK and LOCKSMITH: complementary hydropathic map predictions of drug structure from a known receptor-receptor structure from known drugs. J. Mol. Graph. 1992, 10:212-217.
16. http://www.moldiscovery.com.
17. Cruciani G., Watson K.A. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. J. Med. Chem. 1994, 37:2589-2601.
18. Elkins S., Waller C.L., Swaan P.W., Cruciani G., Wrighton S.A., Wikel J.H. Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Meth. 2000, 44:251-272.
19. Anzeabacherova E., Bec N., Anzenbacher P., Hudecek J., Soucek P., Jung C., Munto A.W., Lange R. Flexibility and stability of the structure of cytochromes P450 3A4 and BM-3. Eur. J. Biochem. 2000, 267:2916-2920.
20. Arnold G.E., Ornstein R.L. Molecular dynamics study of time-correlated protein domain motions and molecular flexibility: cytochrome P450BM-3. Biophys. J. 1997, 73:1147-1159.
21. Clark M., Cramer R., Jones D., Patterson D., Simeroth P. Comparative molecular field analysis (CoMFA): 2. Toward its use with 3D-structural databases. Tetrahedron Comp. Meth. 1990, 3:47.
22. Kearsley S., Smith G. An alternative method for the alignment of molecular structures: maximizing electrostatic and steric overlap. Tetrahedron Comp. Meth. 1990, 3:615.
23. Waller C.L., Oprea T.I., Chae K., Rhee-Park H.-K., Korach K.S., et al. Ligand-based identification of environmental estrogens. Chem. Res. Toxicol. 1996, 9:1240.
24. Klebe G., Mietzner T., Weber F. Different approaches toward an automatic structural alignment of drug molecules: applications to sterol mimics, thrombin and thermolysin inhibitors. J. Comput.-Aided Mol. Design. 1994, 8:751.
25. Lemmen C., Lengauer T. Computational methods for the structural alignment of molecules. J. Comput.-Aided Mol. Design 2000, 14:215-232.
26. Cruciani G., Clementi S. GOLPE philosophy and applications in 3D-QSAR. Advanced Computer-Assisted Tecniques in Drug Discovery 1994, 305-330. VCH, Weinheim. H. Van de Waterbeemd (Ed.).
27. Cruciani G., Goodford P.J. A search for specificity in DNA-drug interactions. J. Mol. Graph. 1994, 12:116-129.
28. Wold S., Esbensen K., Geladi P. Principal component analysis. Chemometrics Intellig. Lab. Syst. 1987, 2:37-52.
29. Westerhuis J.A., Kourti T., Macgregor J.F. Analysis of multiblock and hierarchical PCA and PLS models. J. Chemometrics 1998, 12:301-321.
30. Crivori P., Cruciani G., Carrupt P.A., Testa B. Predicting blood-brain barrier permeation from the three-dimensional molecular structure. J. Med. Chem. 2000, 43:2204-2216.
31. 2 cannabinoid receptors. J. Med. Chem. 2000, 43:2300-2309.
32. Cruciani G., Goodford P.J. A search for specificity in DNA-drug interactions. J. Mol. Graph. 1994, 12:116-129.
33. Pastor M., Cruciani G. A novel strategy for improving ligand selectivity in receptor-based drug design. J. Med. Chem. 1995, 38:4637-4647.
34. Matter H., Schwab W. Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins. J. Med. Chem. 1999, 42:4506-4523.
35. Kastenholz M.K., Pastor M., Cruciani G., Haaksma E.E.J., Fox T. GRID/CPCA: A new computational tool to design selective ligands. J. Med. Chem. 2000, 43:3033-3044.
36. Davie E.W., Fujikawa K., Kisiel W. The coagulation cascade: initiation, maintenance, and regulation (review). Biochemistry 1991, 30:10363-10370.
37. Kaiser B. Thrombin and factor Xa inhibitors. Drugs Fut. 1998, 23:423-436.
38. Wiley M.R., Fisher M.J. Small-molecule direct thrombin inhibitors. Exp. Opin. Ther. Patents 1997, 7:1265-1282.
39. Tapparelli C., Metternich R., Ehrhardt C., Cook N.S. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile (review). Trends Pharmacol. Sci. 1993, 14:366-376.
40. Hauptmann J., Stürzebecher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb. Res. 1999, 93:203-241.
41. Babine R.E., Bender S.L. Molecular recognition of protein-ligand complexes: applications to drug design. Chem. Rev. 1997, 97:1359-1472.
42. Claeson G., Elgendy S., Cheng L., Chino N., Goodwin C.A., Scully M.F., Deadman J. Design of novel types of thrombin inhibitors based on modified d-Phe-Pro-Arg sequences. Adv. Exp. Med. Biol. 1993, 340:83-89.
43. Krishnan R., Zhang E., Hakansson K., Arni R.K., Tulinsky A., et al. Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes. Biochem. 1998, 37:12094-12103.
44. Stubbs M.T., Bode W. A player of many parts: The spotlight falls on thrombin's structure. Thromb. Res. 1993, 69:1-58.
45. Cruciani G., Pastor M., Clementi S. Handling information from 3D grid maps for QSAR studies. Molecular Modeling and Prediction of Bioactivity 1999, Kluwer, Weinheim. K. Gundertofte, F.S. Jorgensen (Eds.).
46. http://www.rcsb.org/pdb/index.html.
47. Goodford P. GRID 1998, 17. version.
48. Feng D.-M., Gardell S.-J., Lewis S.D., Bock M.G., Chen Z., et al. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position. J. Med. Chem. 1997, 40:3726-3733.
49. Sanderson P.E.J., Cutrona K.J., Dorsey B.D., Dyer D.L. L-374.087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorg. Med. Chem. Lett. 1998, 8:817-822.
50. Malikayil J.A., Burkhart J.P., Schreuder H.A., Broersma R.J., Tardif C., et al. Molecular design and characterization of an Alpha-thrombin inhibitor containing a novel PI moiety. Biochemistry 1997, 36:1034-1040.
51. Rewinkel J.B.M., Lucas H., van Galen P.J.M., Noarch A.B.J., van Dinther T.G., et al. 1-aminoisoquinoline as benzamidine isostere in the design and synthesis of orally active thrombin inhibitors. Bioorg. Med. Chem. Lett. 1999, 9:685-690.
52. Stürzebecher J., Prasa D., Hauptmann J., Vieweg H., Wikström P. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J. Med. Chem. 1997, 40:3091-3099.
53. Al-Obeidi F., Ostrem J.A. Factor Xa inhibitors. Exp. Opin. Thes. Pat. 1999, 9:931-953.
54. Phillips G., Davey D.D., Eagen K.A., Koovakkat S.K., Liang A., et al. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors. J. Med. Chem. 1999, 42:1749-1756.
55. Gabriel B., Stubbs M.T., Bergner A., Hauptmann J., Bode W., et al. Design of benzamidine-type inhibitors of factor Xa. J. Med. Chem. 1998, 41:4240-4250.
56. Pastor M., Cruciani G., McLay I., Pickett S., Clementi S. GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. J. Med. Chem. 2000, 43:3233-3243.
57. Benedetti P., Mannhold R., Cruciani G., Pastor M. GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND). J. Med. Chem. 2002, 44:2486-2489.